Total Payments
$2.9M
2024 Payments
$324,618
Companies
48
Transactions
3,240
Medicare Patients
50,536
Medicare Billing
$7.7M
Payment Breakdown by Category
Other$1.7M (58.3%)
Consulting$758,933 (26.2%)
Research$208,268 (7.2%)
Travel$187,816 (6.5%)
Food & Beverage$51,574 (1.8%)
Education$328.13 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 547 | 57.5% |
| Consulting Fee | $758,933 | 285 | 26.2% |
| Unspecified | $208,268 | 58 | 7.2% |
| Travel and Lodging | $187,816 | 884 | 6.5% |
| Food and Beverage | $51,574 | 1,446 | 1.8% |
| Honoraria | $20,808 | 7 | 0.7% |
| Education | $328.13 | 13 | 0.0% |
Payments by Type
General
$2.7M
3,182 transactions
Research
$208,268
58 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $962,958 | 820 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $329,477 | 212 | $0 (2024) |
| Lilly USA, LLC | $312,925 | 370 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $197,029 | 261 | $0 (2024) |
| UCB, Inc. | $166,699 | 150 | $0 (2024) |
| Janssen Biotech, Inc. | $163,406 | 306 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $142,347 | 120 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $123,708 | 151 | $0 (2024) |
| GENZYME CORPORATION | $120,017 | 114 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $56,948 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $324,618 | 377 | ABBVIE INC. ($110,336) |
| 2023 | $287,228 | 379 | AbbVie Inc. ($93,494) |
| 2022 | $414,709 | 384 | ABBVIE INC. ($151,512) |
| 2021 | $219,885 | 161 | AbbVie Inc. ($51,135) |
| 2020 | $215,748 | 149 | AbbVie Inc. ($92,523) |
| 2019 | $456,617 | 558 | AbbVie, Inc. ($175,938) |
| 2018 | $570,424 | 671 | AbbVie, Inc. ($179,369) |
| 2017 | $402,531 | 561 | AbbVie, Inc. ($108,652) |
All Payment Transactions
3,240 individual payment records from CMS Open Payments — Page 1 of 130
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $199.14 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/24/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 12/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $25.93 | General |
| Category: Immunology | ||||||
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $117.56 | General |
| Category: Immunology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $24.33 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Immunology | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,150.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $156.78 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: Dermatology | ||||||
| 11/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 11/26/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Inflammation | ||||||
| 11/22/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,760.00 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $21.22 | General |
| Category: Dermatology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $99.60 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M15-997 | AbbVie, Inc. | $146,772 | 35 |
| M15-997 | AbbVie Inc. | $27,611 | 8 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $12,508 | 2 |
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD | Eli Lilly and Company | $8,558 | 2 |
| H13-147 | AbbVie, Inc. | $3,900 | 1 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $2,634 | 2 |
| Ph4 Otezla in oligoarticular PsA FOREMOST/KEG | Amgen Inc. | $1,898 | 1 |
| CC-10004-PSA-004 | Celgene Corporation | $1,488 | 1 |
| CC-10004-PSOR-008 CC-10004-PSOR-009 | Celgene Corporation | $578.00 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD AND A LONG TERM EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $393.50 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $282.38 | 1 |
| A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $174.68 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 66 | 11,861 | 32,658 | $4.6M | $2.3M |
| 2022 | 69 | 13,344 | 32,928 | $4.5M | $2.2M |
| 2021 | 71 | 13,653 | 28,830 | $4.0M | $1.9M |
| 2020 | 66 | 11,678 | 23,516 | $2.8M | $1.2M |
Total Patients
50,536
Total Services
117,932
Medicare Billing
$7.7M
Procedure Codes
272
All Medicare Procedures & Services
272 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2023 | 29 | 9,700 | $1.7M | $1.1M | 62.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 2,029 | 2,548 | $318,560 | $169,033 | 53.1% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 214 | 281 | $281,000 | $128,878 | 45.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 1,278 | 2,287 | $343,050 | $127,237 | 37.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 1,798 | 2,255 | $225,500 | $89,414 | 39.7% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 148 | 239 | $143,400 | $82,352 | 57.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 647 | 716 | $128,880 | $54,970 | 42.7% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 92 | 187 | $93,500 | $54,303 | 58.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 1,543 | 9,387 | $187,740 | $48,213 | 25.7% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 88 | 151 | $60,400 | $35,615 | 59.0% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 142 | 149 | $67,050 | $31,811 | 47.4% |
| 17281 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 201 | 246 | $73,800 | $30,364 | 41.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 202 | 239 | $59,750 | $30,244 | 50.6% |
| 15260 | Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | Office | 2023 | 28 | 29 | $46,400 | $23,943 | 51.6% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 212 | 253 | $55,660 | $23,455 | 42.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 339 | 386 | $55,970 | $23,403 | 41.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 500 | 540 | $43,250 | $22,713 | 52.5% |
| 17271 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | Office | 2023 | 167 | 207 | $51,750 | $21,226 | 41.0% |
| 12052 | Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | Office | 2023 | 77 | 77 | $34,650 | $17,047 | 49.2% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 100 | 124 | $32,240 | $14,979 | 46.5% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2023 | 57 | 61 | $42,700 | $14,961 | 35.0% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2023 | 25 | 29 | $26,100 | $13,329 | 51.1% |
| 17314 | Removal and microscopic exam of growth of trunk, arms, or legs, each additional stage, 1-5 tissue blocks | Office | 2023 | 22 | 33 | $19,800 | $10,941 | 55.3% |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 71 | 85 | $25,500 | $10,840 | 42.5% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 44 | 46 | $27,600 | $10,343 | 37.5% |
About Dr. Jeffrey Crowley, M.D
Dr. Jeffrey Crowley, M.D is a MOHS-Micrographic Surgery healthcare provider based in Bakersfield, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073500278.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Crowley, M.D has received a total of $2.9M in payments from pharmaceutical and medical device companies, with $324,618 received in 2024. These payments were reported across 3,240 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.7M).
As a Medicare-enrolled provider, Crowley has provided services to 50,536 Medicare beneficiaries, totaling 117,932 services with total Medicare billing of $7.7M. Data is available for 4 years (2020–2023), covering 272 distinct procedure/service records.
Ad
Practice Information
- Specialty MOHS-Micrographic Surgery
- Other Specialties Clinical & Laboratory Dermatological Immunology, Dermatology
- Location Bakersfield, CA
- Active Since 10/03/2005
- Last Updated 09/07/2011
- Taxonomy Code 207ND0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1073500278
Products in Payments
- TALTZ (Drug) $276,468
- TREMFYA (Drug) $275,819
- SKYRIZI (Biological) $249,669
- COSENTYX (Biological) $192,631
- RINVOQ (Biological) $182,000
- Humira (Biological) $163,179
- Tremfya (Drug) $150,432
- DUPIXENT (Biological) $137,852
- Skyrizi (Biological) $106,269
- Sotyktu (Drug) $95,004
- Bimzelx (Biological) $76,355
- Cimzia (Drug) $65,815
- STELARA (Biological) $60,030
- DUPIXENT (Drug) $46,438
- DUPIXENT DUPILUMAB INJECTION (Biological) $44,634
- Otezla (Drug) $44,038
- Zoryve (Drug) $31,287
- Enbrel (Biological) $28,188
- ATOPIC DERMATITIS - DISEASE (Drug) $25,508
- ILUMYA (Biological) $19,596
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.